The invention relates to DNA polymorphisms in sterol regulator element
binding proteins (SREBP) that are characteristic of a higher risk of
genetic diseases in humans such as hyperchlolesterolemia. The
corresponding polymorphisms, especially the polymorphisms on SREBP-1 and
SREBP-2 are frequently observed in Alzheimer patients (SREBP-2). They are
also characterized by a specific behavior in the therapy of HIV patients
with proteas inhibitors and appear to have an influence on the mortality.